Policy & Regulation
Bridge Biotherapeutics commences BBT-176 phase one/two clinical trial
7 April 2021 -

Bridge Biotherapeutics Inc (288330 KQ), a Republic of Korea-based clinical-stage biotech company, has started the phase one/two clinical trial evaluating safety, tolerability, and anti-tumour activity of BBT-176 in non-small cell lung cancer (NSCLC) patients who acquired osimertinib-resistant EGFR triple mutations, it was reported on Tuesday.

The product is a novel epidermal growth factor receptor-tyrosine kinase inhibitor and is designed to inhibit the signalling pathway of EGFR with C797S mutations, which is the result of osimertinib (Tagrisso)-resistant mutations in NSCLC.

The phase one/two study is an open-label study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumour activity of BBT-176 in patients with NSCLC who progressed following prior therapy with an EGFR TKI agent (NCT identifier: NCT04820023). It is likely to enrol around 90 participants separated into two parts: a dose escalation phase (Part one) and a dose expansion phase (Part two).

Additional information about the clinical trial may be found at ClinicalTrials.gov, using identifier NCT: 04820023.



Related Headlines